Clinical Trial

Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis

Study acronym: ОС26
Recruiting
View on ClinicalTrials.gov →
Summary
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
Protocol Amendment History 4 changes
critical Recruitment opened 2026-05-29
notable Primary completion moved earlier: 2026-10-01 -> 2026-05-01 2026-05-29
minor Completion moved earlier: 2026-12-31 -> 2026-12-01 2026-05-29
critical Primary endpoint(s) modified 2026-05-20
Trial Details
NCT Number NCT07536841
Lead Sponsor Military Medical Clinical Center of the Southern Region, Ukraine
Conditions Autoimmune Pancreatitis, IgG4-Related Diseases, Pancreatic Cancer, Chronic Pancreatitis
Enrollment 82 participants
Start Date 2026-05-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-28